Events for the full year 2012
Laquinimod
- Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)
- Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva
- Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study) in the US
- Positive Crohn's Phase II data presented at the UEGW conference
- Teva expands the clinical development program to encompass new indications
TASQ
- EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase III study
- overall survival data from Phase II study presented
- biomarker data presented at the ESMO conference
- Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate cancer and
a second study into additional cancer forms - Phase III study fully enrolled (1,245 patients); milestone payment of EUR 10 M from Ipsen
ANYARA
- Phase II/III study in renal cell cancer concluded
- Results presented during Q1, 2013:
- study did not achieve primary clinical endpoint
- doubling of progression free survival and OS in 25 % of patients
- planning of the continued clinical development ongoing
57-57
- clinical trial of systemic sclerosis/scleroderma concluded
ISI
- focus on patent submissions H1 2013
- project proceeds as planned
| Oct - Dec | Jan - Dec | |||
| (MSEK) | 2012 | 2011 | 2012 | 2011 |
| 91.5 | 3.3 | 227.9 | 234.6 |
| 5.5 | -94.7 | -163.2 | -100.9 |
| 0.1 | -93.2 | -175.0 | -94.5 |
| 0.00 | -1.35 | -2.54 | -1.38 |
For further information, please contact:
Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95
Hans Kolam, CFO Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00, Fax +46 (0)46 19 11 00
This report is also available at www.activebiotech.com
